These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29731231)

  • 1. Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist.
    Spoerri PM; Kato HE; Pfreundschuh M; Mari SA; Serdiuk T; Thoma J; Sapra KT; Zhang C; Kobilka BK; Müller DJ
    Structure; 2018 Jun; 26(6):829-838.e4. PubMed ID: 29731231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational Plasticity of Human Protease-Activated Receptor 1 upon Antagonist- and Agonist-Binding.
    Spoerri PM; Sapra KT; Zhang C; Mari SA; Kato HE; Kobilka BK; Müller DJ
    Structure; 2019 Oct; 27(10):1517-1526.e3. PubMed ID: 31422910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
    Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
    Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule.
    Bokoch MP; Jo H; Valcourt JR; Srinivasan Y; Pan AC; Capponi S; Grabe M; Dror RO; Shaw DE; DeGrado WF; Coughlin SR
    Biochemistry; 2018 Oct; 57(39):5748-5758. PubMed ID: 30102523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating detailed interactions between novel PAR1 antagonist F16357 and the receptor using docking and molecular dynamic simulations.
    Readmond C; Wu C
    J Mol Graph Model; 2017 Oct; 77():205-217. PubMed ID: 28881236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution crystal structure of human protease-activated receptor 1.
    Zhang C; Srinivasan Y; Arlow DH; Fung JJ; Palmer D; Zheng Y; Green HF; Pandey A; Dror RO; Shaw DE; Weis WI; Coughlin SR; Kobilka BK
    Nature; 2012 Dec; 492(7429):387-92. PubMed ID: 23222541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
    Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
    Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia.
    Schoergenhofer C; Schwameis M; Gelbenegger G; Buchtele N; Thaler B; Mussbacher M; Schabbauer G; Wojta J; Jilma-Stohlawetz P; Jilma B
    Thromb Haemost; 2018 Jul; 118(7):1176-1184. PubMed ID: 29864779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation.
    Friebel J; Moritz E; Witkowski M; Jakobs K; Strässler E; Dörner A; Steffens D; Puccini M; Lammel S; Glauben R; Nowak F; Kränkel N; Haghikia A; Moos V; Schutheiss HP; Felix SB; Landmesser U; Rauch BH; Rauch U
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PAR1: Now What?
    Flaumenhaft R; De Ceunynck K
    Trends Pharmacol Sci; 2017 Aug; 38(8):701-716. PubMed ID: 28558960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics.
    van den Eshof BL; Hoogendijk AJ; Simpson PJ; van Alphen FPJ; Zanivan S; Mertens K; Meijer AB; van den Biggelaar M
    Arterioscler Thromb Vasc Biol; 2017 Oct; 37(10):1891-1902. PubMed ID: 28818855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorapaxar for the reduction of atherothrombotic events.
    Diaz-Ricart M; Escolar G
    Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
    French SL; Arthur JF; Tran HA; Hamilton JR
    Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar.
    Aisiku O; Peters CG; De Ceunynck K; Ghosh CC; Dilks JR; Fustolo-Gunnink SF; Huang M; Dockendorff C; Parikh SM; Flaumenhaft R
    Blood; 2015 Mar; 125(12):1976-85. PubMed ID: 25587041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorapaxar in the secondary prevention of atherothrombosis.
    Tantry US; Liu F; Chen G; Gurbel PA
    Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.
    Gandhi DM; Majewski MW; Rosas R; Kentala K; Foster TJ; Greve E; Dockendorff C
    Bioorg Med Chem; 2018 May; 26(9):2514-2529. PubMed ID: 29685684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease-Activated Receptors 1 and 3 are Differentially Expressed on Human Monocyte Subsets and are Upregulated by Lipopolysaccharide Ex Vivo and In Vivo.
    Thaler B; Hohensinner PJ; Baumgartner J; Haider P; Krychtiuk KA; Schörgenhofer C; Jilma B; Hell L; Fischer MB; Huber K; Hengstenberg C; Speidl WS; Wojta J
    Thromb Haemost; 2019 Sep; 119(9):1394-1402. PubMed ID: 31291665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteinase-activated receptors (PARs) as targets for antiplatelet therapy.
    Cunningham M; McIntosh K; Bushell T; Sloan G; Plevin R
    Biochem Soc Trans; 2016 Apr; 44(2):606-12. PubMed ID: 27068977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.
    Gryka RJ; Buckley LF; Anderson SM
    Drugs R D; 2017 Mar; 17(1):65-72. PubMed ID: 28063023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging G protein-coupled receptors while quantifying their ligand-binding free-energy landscape.
    Alsteens D; Pfreundschuh M; Zhang C; Spoerri PM; Coughlin SR; Kobilka BK; Müller DJ
    Nat Methods; 2015 Sep; 12(9):845-851. PubMed ID: 26167642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.